Anthera Announces Completion of Safety Review by DSMB for VISTA-16

Loading...
Loading...
Anthera Pharmaceuticals, Inc.
ANTH
today announced that the VISTA-16 Data Safety Monitoring Board (DSMB) has met for the fifth time to review available safety data and has recommended the study continue without change. The Company is awaiting the assessment of a pre-defined interim efficacy analysis of the primary endpoint, which is scheduled to occur after 50% of the primary endpoint events in the VISTA-16 clinical study have been collected, adjudicated and reviewed by the DSMB. The primary endpoint of the VISTA-16 study is a composite of the time to occurrence of a secondary major adverse cardiovascular event consisting of unstable angina requiring urgent hospitalization, myocardial infarction, stroke and cardiovascular death.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...